PF-Atlas › Drugs › ROCK Inhibitor — Inhaled Fasudil

ROCK Inhibitor — Inhaled Fasudil

Idiopathic Pulmonary Fibrosis · Reduces cytoskeletal tension, reverses myofibroblast — breaks ECM stiffness loop

Mechanism
Reduces cytoskeletal tension, reverses myofibroblast — breaks ECM stiffness loop
Development stage
Phase II
Evidence level
Level 2 (Phase II Japan)
Developer
Multiple (Japan)

Overview

Fasudil approved in Japan for other uses. Inhaled formulation reduces systemic BP effects. Softens fibrotic matrix.

Explore related

Treatment profileReduces cytoskeletal tension, reverses myofibroblast — breaks ECM stiffness loopAll trialsResearch
Medical disclaimer. This page summarizes research about ROCK Inhibitor — Inhaled Fasudil for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.